KIT and gastrointestinal stromal tumor: The result in this study is very similar to the just released phase III study (INTRIGUE) of ripretinib versus sunitinib in GIST second-line treatment.12,13 Ripretinib, as an activation loop switch inhibitor, showed significant inhibitory effect on the different KIT mutant GIST cell line and was approved as a fourth-line treatment for metastatic GIST.14 Interestingly, PFS of 8.0 months and 8.3 months were obtained in INTRIGUE study of ripretinib and sunitinib, respectively, similar to that of anlotinib in the current study.12